CN1856295A - 控释组合物 - Google Patents
控释组合物 Download PDFInfo
- Publication number
- CN1856295A CN1856295A CNA2004800272439A CN200480027243A CN1856295A CN 1856295 A CN1856295 A CN 1856295A CN A2004800272439 A CNA2004800272439 A CN A2004800272439A CN 200480027243 A CN200480027243 A CN 200480027243A CN 1856295 A CN1856295 A CN 1856295A
- Authority
- CN
- China
- Prior art keywords
- poly
- compositions
- bioactivator
- acid
- organic ion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
有机相中的共溶剂 | 水相成分 | 中值粒径 | 核载药量(包封率) | 突释率(%) | 肽释放总量(酰化的) | |
ABCDD2EF | PEG200(100μL)PEG400(100μL)MeOH(50μL)MeOH(100μL)MeOH(100μL)DMF(100μL)DMSO(100μL) | 1%PVA1%PVA1%PVA1%PVA+10mM PO4(pH8)1%PVA+10mM PO4(pH8)1%PVA1%PVA | 49μm76μm25μm34μm60μm38μm38μm | 2.83%(28%)3.20%(32%)2.75%(28%)5.57%(56%)5.66%(57%)3.41%(34%)4.88%(49%) | 7.9610.42.912.581.901.972.74 | 72.6%(44%)63.0%(48%)65.7%(50%)65.1%(50%)85.8%(55%)50.3%(33%)43.4%(36%) |
制剂D2 | ||
100mM NaOAc(pH4) | ||
天 | 肽释放率% | 酰化肽释放率% |
0 | 0.0 | 0.0 |
1 | 5.55 | 0.15 |
3 | 13.75 | 0.78 |
6 | 53.47 | 4.11 |
10 | 71.74 | 5.16 |
14 | 72.19 | 5.26 |
20 | 72.21 | 5.28 |
24 | 72.22 | 5.30 |
29 | 72.22 | 5.30 |
34 | 72.22 | 5.30 |
42 | 72.22 | 5.30 |
48 | 72.22 | 5.30 |
制剂D2 | ||
PBS(pH7) | ||
天 | 肽释放率% | 酰化肽释放率% |
0 | 0.0 | 0.0 |
1 | 1.81 | 0.08 |
3 | 3.09 | 0.22 |
6 | 4.87 | 0.59 |
10 | 7.54 | 1.98 |
14 | 10.42 | 4.29 |
20 | 17.81 | 10.51 |
24 | 20.69 | 14.06 |
29 | 23.86 | 18.86 |
34 | 26.21 | 23.12 |
42 | 32.91 | 28.73 |
48 | 35.13 | 32.14 |
57 | 36.50 | 35.10 |
64 | 37.83 | 37.41 |
71 | 38.42 | 45.82 |
78 | 38.58 | 46.37 |
85 | 38.64 | 46.70 |
制剂AG | ||
PBS(pH7) | ||
天 | 肽释放率% | 酰化肽释放率% |
0 | 0.0 | 0.0 |
1 | 8.04 | 0.33 |
2 | 9.09 | 0.47 |
6 | 12.27 | 0.65 |
15 | 17.75 | 1.23 |
24 | 20.03 | 1.78 |
29 | 23.78 | 2.66 |
35 | 36.16 | 5.62 |
42 | 43.80 | 8.15 |
49 | 51.17 | 11.13 |
57 | 61.47 | 15.57 |
64 | 67.63 | 18.16 |
制剂 | 有机相中的共溶剂 | 中值粒径 | 核载药量(包封率) | 突释率(酰化的) |
GHI | MeOH(100μL)MeOH(100μL)MeOH(200μL) | 11.4μm12.4μm12.9μm | 0.61%(6.1%)0.75%(7.5%)2.64%(2.6%) | 20.3%(49%)21.2%(40%)20.2%(42%) |
制剂 | 有机相中的共溶剂 | 苯甲酸∶醋酸奥曲肽比例 | 中值粒径 | 核载药量(包封率) |
JKLM | MeOH(100μL)MeOH(100μL)MeOH(100μL)MeOH(100μL) | 12510 | 21.8μm19.5μm18.8μm17.9μm | 1.36%(14%)0.88%(8.8%)1.61%(16%)1.67%(17%) |
制剂 | 奥曲肽/双羟萘酸盐比例起始(最终) | 有机相中的共溶剂 | 中值粒径 | 核载药量(包封率) | 肽释放总量(酰化的) |
QRSTUVW | 1.7∶1(4.4∶1)1.7∶1(201∶1)1.7∶1(13∶1)1.7∶1(21∶1)1∶1(5.3∶1)1∶1(5.4∶1)1∶1(2.1∶1) | MeOH(100μL)MeOH(500μL)BnOH(200μL)MeOH(200μL)MeOH(200μL)BnOH(200μL)BnOH(200μL) | 40μm34μm31μm37μm48μm48μm44μm | 6.52%(65%)3.34%(33%)8.29%(83%)5.03%(50%)4.93%(49%)4.76%(48%)5.01%(25%) | 88.6%(28.1%)79.2%(38.9%)87.2%(39.7%)91.5%(32.2%)92.3%(37.3%)110%(44.4%)84.9%(35.0%) |
制剂(奥曲肽/双羟萘酸盐最终比例) | 醋酸奥曲肽加入量 | 共溶剂 | 有机相/水相比例 | 中值粒径 | 核载药量(包封率) | 肽释放总量(酰化的) |
X(1.09∶1)Y(0.86∶1)Z(1.09∶1)AA(1.01∶1)AB(1.11∶1)AC(1.14∶1)AD(1.11∶1)AE(1.41∶1)AF(1.16∶1)AG(1.39∶1)AH(1.36∶1)AI | 40mg20mg20mg20mg20mg20mg40mg60mg60mg60mg60mg60mg | MeOH(200μL)MeOH(200μL)BnOH(1000μL)BnOH(1000μL)BnOH(500μL)BnOH(1000μL)BnOH(1000)μLBnOH(500μL)BnOH(500μL)BnOH(1000μL)BnOH(1000μL)BnOH(1000μL) | 1∶41∶101∶21∶21∶21∶21∶21∶21∶41∶21∶21∶2 | 79μm71μm44μm59μm45μm47μm53μm45μm50μm39μm37μm40μm | 8.52%(46.8%)5.13%(51%)7.61%(76%)6.79%(6.8%)6.19%(62%)7.51%(75%)12.7%(64%)9.51%(32%)12.0%(40%)17.2%(57%)17.5%(57%)6.85%(23%) | 98.8%(15.7%)120%(30.6%)97.1%(4.11%)101%(12.7%)97.1%(14.8%)96.8%(13.4%)101%(16.1%)103%(26.1%)108%(21.7%)92.5%(20.7%)111%(25.0%)ND |
制剂(奥曲肽/双羟萘酸盐最终比例) | 双羟萘酸钠浓度 | 有机相/水相比例 | 中位粒径 | 核载药量(包封率) | PBS突释率 | 肽释放总量(酰化的) |
AJ(1.33∶1)AK(1.29∶1)AL(1.29∶1) | 20mM20mM50mM | 1∶11∶21∶2 | 33μm41μm54μm | 13.3%(67%)13.3%(67%)12.8%(64%) | 3.77%3.38%15.0% | 108%(25.7%)106%(22.4%)110%(26.8%) |
制剂 | 有机酸钠盐(浓度) | 粒径 | 核载药量(包封率) | 肽释放总量(酰化的) |
AMANAOAPAQARASATAUAVAWAXAYAZBABB | 琥珀酸盐(10mM)苯甲酸盐(10mM)水杨酸盐(10mM)三氟甲基对甲基苯甲酸盐(10mM)胆酸盐(20mM)2-萘磺酸盐(20mM)2,3-萘二甲酸盐(10mM)双羟萘酸盐(10mM)双羟萘酸盐(10mM)1-羟基-2-萘甲酸盐(20mM)3-羟基-2-萘甲酸盐(20mM)2-萘甲酸盐(20mM)双羟萘酸盐(10mM)2-萘磺酸盐(20mM)2,3-萘二甲酸盐(10mM)水杨酰水杨酸盐(20mM) | 34.1μm32μm34μm33μm60μm38μm38μm45μm43μm42μm40μm39μm46μm36μm46μm39μm | 7.74%(39%)6.88%(34%)7.78%(39%)8.92%(45%)13.2%(66%)11.6%(58%)13.1%(66%)13.8(69%)14.2%(71%)15.3%(76%)14.6%(72%)13.4%(67%)14.4%(72%)10.8%(54%)12.1%(61%)12.4%(62%) | 99.9%(53.4%)105%(56.7%)106%(54.0%)107%(50.7%)104%(47.2%)110%(42.6%)109%(47%)98.5%(37%)97.5%(31%)152%(25.7%)105%(20.8%)134%(32.9%)103%(22%)138%(33.0%)97.8%(25%)114%(23.2%) |
制剂 | 肽 | 双羟萘酸盐浓度 | 核包封量 | 包封率 |
BIBJBKBLBM | 亮丙瑞林亮丙瑞林亮丙瑞林催产素催产素 | 0mM10mM50mM0mM10mM | 2.0%9.4%10.6%1.7%8.9% | 10.0%47.0%53.0%16.7%49.1% |
制剂 | 剂量(mg/Kg) | 取样天 | |||||
0 | 0.04 | 0.25 | 1 | 4 | 7 | ||
BCBDBEBFBGBH | 10.28.99.78.69.29.411 | 0.000.000.000.000.000.0014 | 39.7539.9536.3539.7529.7039.8020 | 3.834.004.093.893.824.1328 | 0.620.952.041.332.062.9042 | 1.441.662.132.541.853.7054 | 3.073.412.593.062.283.64 |
BCBDBEBFBGBH | 3.713.642.893.161.963.54 | 3.423.442.942.892.003.44 | 3.512.032.191.431.702.34 | 1.951.041.810.640.971.70 | 0.390.453.091.522.241.63 | 0.000.000.900.001.390.05 |
Claims (36)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48940203P | 2003-07-23 | 2003-07-23 | |
US60/489,402 | 2003-07-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1856295A true CN1856295A (zh) | 2006-11-01 |
CN100588423C CN100588423C (zh) | 2010-02-10 |
Family
ID=34102864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200480027243A Expired - Fee Related CN100588423C (zh) | 2003-07-23 | 2004-07-15 | 控释组合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8900636B2 (zh) |
EP (2) | EP2444069B1 (zh) |
JP (2) | JP5165240B2 (zh) |
CN (1) | CN100588423C (zh) |
AU (1) | AU2004259209A1 (zh) |
BR (1) | BRPI0412211A (zh) |
CA (1) | CA2533592C (zh) |
ES (1) | ES2741576T3 (zh) |
WO (1) | WO2005009357A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104822370A (zh) * | 2012-09-17 | 2015-08-05 | 佰恩德治疗股份有限公司 | 包含治疗剂的治疗性纳米颗粒及其制备和使用方法 |
CN105555315A (zh) * | 2013-09-16 | 2016-05-04 | 阿斯利康(瑞典)有限公司 | 治疗性聚合物纳米颗粒及其制备和使用方法 |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0409032A (pt) * | 2003-04-10 | 2006-05-02 | Pr Pharmaceuticals | método para a produção de micropartìculas à base de emulsão |
US8871269B2 (en) | 2003-07-15 | 2014-10-28 | Evonik Corporation | Method for the preparation of controlled release formulations |
CA2533592C (en) | 2003-07-23 | 2015-11-10 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
KR101245919B1 (ko) * | 2005-12-22 | 2013-03-20 | 노파르티스 아게 | 옥트레오티드 및 2종 이상의 폴리락티드-코-글리콜리드중합체를 포함하는 서방형 제제 |
KR100816065B1 (ko) * | 2006-11-27 | 2008-03-24 | 동국제약 주식회사 | 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐 |
CL2007003658A1 (es) | 2006-12-18 | 2008-05-09 | Takeda Pharmaceutical | Composicion de liberacion sostenida que comprende un peptido; procedimiento para preparar dicha composicion; agente profilactico o terapeutico para cancer de prostata, hiperplasia prostatica, endometriosis, fibroide uterino, fibroma uterino, pubertad |
NZ581836A (en) * | 2007-06-11 | 2012-07-27 | R Loch Macdonald | A drug delivery system for the prevention of cerebral vasospasm |
US10092524B2 (en) | 2008-06-11 | 2018-10-09 | Edge Therapeutics, Inc. | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage |
KR101921800B1 (ko) | 2008-01-30 | 2018-11-23 | 노파르티스 아게 | 옥트레오티드 및 3종의 선형 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제 |
EP2273986A2 (en) * | 2008-05-06 | 2011-01-19 | Glaxo Group Limited | Encapsulation of biologically active agents |
EA021422B1 (ru) | 2008-06-16 | 2015-06-30 | Бинд Терапьютикс, Инк. | Полимерные наночастицы, содержащие терапевтическое средство, и способ их получения |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
EA020753B1 (ru) | 2008-06-16 | 2015-01-30 | Бинд Терапьютикс, Инк. | Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение |
WO2010009291A1 (en) * | 2008-07-16 | 2010-01-21 | Surmodics Pharmaceuticals, Inc. | Process for preparing microparticles containing bioactive peptides |
CA2735581C (en) | 2008-08-29 | 2017-05-30 | Genzyme Corporation | Controlled-released peptide formulations |
US8563041B2 (en) | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
US20100216804A1 (en) | 2008-12-15 | 2010-08-26 | Zale Stephen E | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents |
US20100266704A1 (en) * | 2008-12-15 | 2010-10-21 | Novartis Ag | Octreotide depot formulation with constantly high exposure levels |
CN102438657A (zh) * | 2009-03-26 | 2012-05-02 | 沃萨乌整形外科公司 | 鉴别定向药物递送组合物的潜在组分的方法 |
IN2012DN00407A (zh) * | 2009-08-05 | 2015-08-21 | Pieris Ag | |
BR112012016021A8 (pt) | 2009-12-11 | 2018-06-12 | Bind Biosciences Inc | Formulações estáveis para liofilização de partículas terapêuticas |
EA201290499A1 (ru) | 2009-12-15 | 2013-01-30 | Байнд Байосайенсиз, Инк. | Композиции терапевтических полимерных наночастиц с высокой температурой стеклования и высокомолекулярными сополимерами |
CA2797098C (en) * | 2010-04-23 | 2019-03-26 | Labopharm Inc. | Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof |
EP2694133B1 (en) | 2011-04-05 | 2018-05-23 | Edge Therapeutics, Inc. | Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow |
US9399019B2 (en) | 2012-05-09 | 2016-07-26 | Evonik Corporation | Polymorph compositions, methods of making, and uses thereof |
JP2015519403A (ja) * | 2012-06-14 | 2015-07-09 | エントレガ,インコーポレイテッド | 活性剤送達のための粘膜付着性デバイス |
BR112015005940A2 (pt) | 2012-09-17 | 2017-07-04 | Bind Therapeutics Inc | processo para a preparação de nanopartículas terapêuticas |
WO2015061442A1 (en) * | 2013-10-22 | 2015-04-30 | Cadila Healthcare Limited | Delayed release pharmaceutical compositions of salsalate |
US20150174254A1 (en) | 2013-12-23 | 2015-06-25 | Mcneil-Ppc, Inc. | Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent |
WO2015123562A1 (en) * | 2014-02-13 | 2015-08-20 | Bind Therapeutics, Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
JP6348616B2 (ja) | 2014-03-14 | 2018-06-27 | ファイザー・インク | 治療剤を含む治療用ナノ粒子ならびにその製造および使用方法 |
US10046058B2 (en) | 2014-12-02 | 2018-08-14 | Rezolute, Inc. | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
GB201622024D0 (en) * | 2016-11-14 | 2017-02-08 | Inventage Lab Inc | Apparatus and method for large scale production of monodisperse, microsheric and biodegradable polymer-based drug delivery |
AU2022226584A1 (en) | 2021-02-24 | 2023-08-17 | Oakwood Laboratories, Llc | Microsphere formulations comprising lurasidone and methods for making and using the same |
WO2024054879A1 (en) * | 2022-09-06 | 2024-03-14 | Regents Of The University Of Michigan | Biodegradable polymeric particles for delivery of positively charged therapeutic agents |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3780195A (en) | 1969-10-22 | 1973-12-18 | Balchem Corp | Encapsulation process |
US3664963A (en) | 1969-10-22 | 1972-05-23 | Balchem Corp | Encapsulation process |
DE2059494B2 (de) | 1970-12-03 | 1972-03-16 | Licentia Gmbh | Biegsamer hohlleiter |
JPS523342B2 (zh) | 1972-01-26 | 1977-01-27 | ||
US3865352A (en) | 1973-11-16 | 1975-02-11 | Minnesota Mining & Mfg | Static mixing device |
DE2604832A1 (de) | 1976-02-07 | 1977-08-11 | Basf Ag | Verfahren zur analyse von loesungen |
US4171981A (en) * | 1977-04-29 | 1979-10-23 | The Mead Corporation | Process for the production of hot melt coating compositions containing microcapsules |
US4183681A (en) | 1978-05-19 | 1980-01-15 | Exxon Research & Engineering Co. | Emulsion preparation method using a packed tube emulsifier |
US4299501A (en) | 1979-08-10 | 1981-11-10 | Ortho Pharmaceutical Corporation | Continuous process for the preparation of semisolid dispersions |
US4384975A (en) * | 1980-06-13 | 1983-05-24 | Sandoz, Inc. | Process for preparation of microspheres |
US4933105A (en) | 1980-06-13 | 1990-06-12 | Sandoz Pharm. Corp. | Process for preparation of microspheres |
US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
DE3732370A1 (de) | 1987-09-25 | 1989-04-06 | Hoechst Ag | Verfahren zur vermischung von lebenden zellen oder mikroorganismen mit einer viskosen fluessigkeit und mischungen, die nach diesem verfahren hergestellt wurden |
AU5741590A (en) | 1989-05-04 | 1990-11-29 | Southern Research Institute | Improved encapsulation process and products therefrom |
PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
US5112604A (en) | 1989-09-01 | 1992-05-12 | Riker Laboratories, Inc. | Oral suspension formulation |
MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
US6120805A (en) * | 1990-04-06 | 2000-09-19 | Rhone-Poulenc Rorer Sa | Microspheres, process for their preparation and their use |
FR2660556B1 (fr) | 1990-04-06 | 1994-09-16 | Rhone Poulenc Sante | Microspheres, leur procede de preparation et leur utilisation. |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
JP3761594B2 (ja) * | 1993-07-05 | 2006-03-29 | 武田薬品工業株式会社 | 徐放性製剤の製造法 |
NZ260909A (en) | 1993-07-05 | 1995-04-27 | Takeda Chemical Industries Ltd | Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution |
AU684324B2 (en) | 1993-11-19 | 1997-12-11 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
GB9412273D0 (en) | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
WO1997004747A1 (en) | 1995-07-27 | 1997-02-13 | Dunn James M | Drug delivery systems for macromolecular drugs |
US5629277A (en) | 1995-10-04 | 1997-05-13 | William L. Brown | Paint removing composition |
US6140040A (en) | 1995-10-06 | 2000-10-31 | Advanced Minerals Corporation | Method of mechanically separating microparticles suspended in fluids using particulate media |
EP0799616A1 (en) | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
US5792477A (en) | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
JPH10109024A (ja) | 1996-10-04 | 1998-04-28 | Jasco Corp | エマルション調整方法及び装置 |
JPH10273447A (ja) * | 1997-01-29 | 1998-10-13 | Takeda Chem Ind Ltd | 徐放性マイクロスフィア、その製造法および用途 |
AU5678398A (en) * | 1997-01-29 | 1998-08-18 | Takeda Chemical Industries Ltd. | Sustained-release microspheres, their production and use |
SE9701161D0 (sv) | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use I |
MY118835A (en) * | 1997-04-18 | 2005-01-31 | Ipsen Pharma Biotech | Sustained release compositions and the process for their preparation |
CA2314934C (en) | 1997-12-16 | 2006-08-29 | Chiron Corporation | Use of microparticles combined with submicron oil-in-water emulsions |
BR9906903A (pt) | 1998-01-16 | 2000-12-12 | Takeda Chemical Industries Ltd | Composição com liberação sustentada, processos para produzir a mesma, para suprimir a brusca liberação inicial da susbtância bioativa de uma composição com liberação sustentada e para aumentar a eficiência da inclusão da substância bioativa em uma composição com liberação sustentada, produto farmacêutico, agente para prevenir ou tratar câncer prostático, hipertrofia prostática, endometriose, histeromioma, metrofibroma, puberdade precoce, dismenorréia, ou câncer do seio, ou um contraceptivo, e, composto |
JPH11349688A (ja) | 1998-06-05 | 1999-12-21 | Reika Kogyo Kk | 徐放性複合エマルション、徐放性微粒子及びその製造方法 |
US6270700B1 (en) | 1998-07-23 | 2001-08-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Encapsulation of water soluble peptides |
JP3012608B1 (ja) | 1998-09-17 | 2000-02-28 | 農林水産省食品総合研究所長 | マイクロチャネル装置及び同装置を用いたエマルションの製造方法 |
US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
EP1044683A1 (en) | 1999-04-15 | 2000-10-18 | Debio Recherche Pharmaceutique S.A. | One-step dispersion method for the microencapsulation of water soluble substances |
US6291013B1 (en) | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
CZ2002114A3 (cs) * | 1999-07-15 | 2002-04-17 | Takeda Chemical Industries, Ltd. | Prostředek s trvalým uvolňováním, způsob jeho výroby a jeho pouľití |
CA2386654A1 (en) | 1999-10-08 | 2001-04-19 | The Procter & Gamble Company | Apparatus and process for in-line preparation of hipes |
US6495166B1 (en) | 1999-11-12 | 2002-12-17 | Alkermes Controlled Therapeutics Inc. | Apparatus and method for preparing microparticles using in-line solvent extraction |
AUPQ529000A0 (en) | 2000-01-28 | 2000-02-17 | Research Laboratories Of Australia Pty Ltd | Toner characterization cell |
US6953593B2 (en) | 2000-02-01 | 2005-10-11 | Lipoprotein Technologies, Inc. | Sustained-release microencapsulated delivery system |
US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US6565873B1 (en) * | 2000-10-25 | 2003-05-20 | Salvona Llc | Biodegradable bioadhesive controlled release system of nano-particles for oral care products |
JP2004534721A (ja) | 2000-10-31 | 2004-11-18 | ピーアール ファーマシューティカルズ,インク. | 生理活性分子の向上した送達のための方法及び組成物 |
EP1352269A2 (en) | 2001-01-15 | 2003-10-15 | 3M Innovative Properties Company | Multilayer infrared reflecting film with high and smooth transmission in visible wavelength region and laminate articles made therefrom |
WO2002058672A2 (en) * | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Microparticles of biodegradable polymer encapsulating a biologically active substance |
TW200526267A (en) | 2001-06-29 | 2005-08-16 | Takeda Chemical Industries Ltd | Controlled release composition and method of producing the same |
WO2003092585A2 (en) | 2002-05-02 | 2003-11-13 | Pr Pharmaceuticals, Inc. | Controlled release compositions of estradiol metabolites |
EP1829529A1 (en) | 2002-05-03 | 2007-09-05 | PR Pharmaceuticals, Inc. | Controlled release compositions of estradiol metabolites |
CA2516098A1 (en) * | 2003-03-05 | 2004-09-16 | Paul S. Hudnut | Oxytocin controlled release formulations and methods of using same |
US20070207211A1 (en) | 2003-04-10 | 2007-09-06 | Pr Pharmaceuticals, Inc. | Emulsion-based microparticles and methods for the production thereof |
BRPI0409032A (pt) | 2003-04-10 | 2006-05-02 | Pr Pharmaceuticals | método para a produção de micropartìculas à base de emulsão |
DK2599502T3 (en) | 2003-04-11 | 2017-04-18 | Antriabio Inc | Process for Preparation of Site-Specific Protein Conjugates |
US8871269B2 (en) | 2003-07-15 | 2014-10-28 | Evonik Corporation | Method for the preparation of controlled release formulations |
CA2533592C (en) | 2003-07-23 | 2015-11-10 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
-
2004
- 2004-07-15 CA CA2533592A patent/CA2533592C/en not_active Expired - Fee Related
- 2004-07-15 AU AU2004259209A patent/AU2004259209A1/en not_active Abandoned
- 2004-07-15 CN CN200480027243A patent/CN100588423C/zh not_active Expired - Fee Related
- 2004-07-15 US US10/565,401 patent/US8900636B2/en active Active
- 2004-07-15 EP EP11187401.2A patent/EP2444069B1/en not_active Expired - Lifetime
- 2004-07-15 EP EP04778361A patent/EP1656115A4/en not_active Ceased
- 2004-07-15 BR BRPI0412211-9A patent/BRPI0412211A/pt not_active IP Right Cessation
- 2004-07-15 ES ES11187401T patent/ES2741576T3/es not_active Expired - Lifetime
- 2004-07-15 JP JP2006521134A patent/JP5165240B2/ja not_active Expired - Fee Related
- 2004-07-15 WO PCT/US2004/022817 patent/WO2005009357A2/en active Application Filing
-
2011
- 2011-04-27 JP JP2011100212A patent/JP2011144208A/ja not_active Withdrawn
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104822370A (zh) * | 2012-09-17 | 2015-08-05 | 佰恩德治疗股份有限公司 | 包含治疗剂的治疗性纳米颗粒及其制备和使用方法 |
CN105555315A (zh) * | 2013-09-16 | 2016-05-04 | 阿斯利康(瑞典)有限公司 | 治疗性聚合物纳米颗粒及其制备和使用方法 |
CN105555315B (zh) * | 2013-09-16 | 2019-05-07 | 阿斯利康(瑞典)有限公司 | 治疗性聚合物纳米颗粒及其制备和使用方法 |
Also Published As
Publication number | Publication date |
---|---|
JP5165240B2 (ja) | 2013-03-21 |
JP2006528179A (ja) | 2006-12-14 |
ES2741576T3 (es) | 2020-02-11 |
EP2444069A1 (en) | 2012-04-25 |
CN100588423C (zh) | 2010-02-10 |
WO2005009357A3 (en) | 2005-11-24 |
EP2444069B1 (en) | 2019-06-05 |
WO2005009357A2 (en) | 2005-02-03 |
EP1656115A4 (en) | 2009-07-08 |
BRPI0412211A (pt) | 2006-08-22 |
JP2011144208A (ja) | 2011-07-28 |
CA2533592A1 (en) | 2005-02-03 |
AU2004259209A1 (en) | 2005-02-03 |
US8900636B2 (en) | 2014-12-02 |
AU2004259209A2 (en) | 2005-02-03 |
EP1656115A2 (en) | 2006-05-17 |
CA2533592C (en) | 2015-11-10 |
US20070092574A1 (en) | 2007-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1856295A (zh) | 控释组合物 | |
CN1852687A (zh) | 控释组合物的制备方法 | |
CN1174742C (zh) | 金属阳离子固定化的干扰素的控制释放 | |
CN1102854C (zh) | 人生长激素的延续释放组合物 | |
CA2565296C (en) | Sustained-release microspheres and methods of making and using same | |
CN1205248C (zh) | 能溶解在有机溶剂中的生物可降解的聚环氧烷-聚(对-二噁烷酮)嵌段共聚物及含该共聚物的药物供送组合物 | |
CN1132625C (zh) | 包胶在透明质酸微粒中的缓释药物组合物 | |
CN1507357A (zh) | 提高生物活性分子传递的方法和组合物 | |
CN1527698A (zh) | 控释可生物降解的凝胶基质 | |
CN101035512A (zh) | 用于生物活性化合物可控制释放递送的药物组合物 | |
CN1054009A (zh) | 缓释微胶囊 | |
CN1188408A (zh) | 新型的“非突发的”持续释放聚(丙交酯/乙交酯)的微球 | |
CN100345535C (zh) | 胰岛素控释制剂及其方法 | |
JP2002226365A (ja) | 生理活性物質含有製剤の製造法 | |
CN1093597A (zh) | 控制释放的可移植的生长激素组合物 | |
CN1732903A (zh) | 一种制备缓释微球的方法 | |
KR20100042768A (ko) | 생분해성 고분자 미립구 및 그 제조방법 | |
CN110090293B (zh) | 一种抑制plga微球中多肽类药物酰化副反应的方法 | |
CN1634570A (zh) | 一种干扰素长效注射微球制剂的制备方法 | |
CN1241139A (zh) | 生产缓释制剂的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: EVONIK LTD. Free format text: FORMER OWNER: SURMODICS SMP INC. Effective date: 20130725 Owner name: BROOKWOOD PHARMACEUTICALS INC. Free format text: FORMER OWNER: PR PHARMACEUTICALS, INC. Effective date: 20130725 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: SURMODICS SMP INC. Free format text: FORMER NAME: PR PHARMACEUTICALS INC. Owner name: PR PHARMACEUTICALS INC. Free format text: FORMER NAME: BROOKWOOD PHARMACEUTICALS INC. |
|
CP01 | Change in the name or title of a patent holder |
Address after: American Delaware Patentee after: PR PHARMACEUTICALS, Inc. Address before: American Delaware Patentee before: Brooke Wood pharmaceuticals Ltd. |
|
CP03 | Change of name, title or address |
Address after: American Minnesota Patentee after: Sur Modi Kors SMP Address before: American Delaware Patentee before: PR PHARMACEUTICALS, Inc. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130725 Address after: American New Jersey Patentee after: Evonik Corp. Address before: American Minnesota Patentee before: Sur Modi Kors SMP Effective date of registration: 20130725 Address after: American Delaware Patentee after: Brooke Wood pharmaceuticals Ltd. Address before: American Colorado Patentee before: PR Pharmaceuticals, Inc. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100210 Termination date: 20180715 |
|
CF01 | Termination of patent right due to non-payment of annual fee |